Use of vouchers and coupons offered by pharmaceutical companies to defray patients’ out-of-pocket drug costs is concentrated among a small number of drugs. While these offsets significantly reduce patient costs, they are not targeted to patients who most need the price reduction, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.